grant
Theranostic Approaches to Breast Cancer Using Image Guided Surgery and Adjuvant PTT
Organization CASE WESTERN RESERVE UNIVERSITYLocation CLEVELAND, UNITED STATESPosted 13 Mar 2026Deadline 28 Feb 2030
NIHUS FederalResearch GrantFY20264T1AblationAbscissionAddressAdjuvantAdjuvant TherapyAnimalsBALB C MouseBALB/cBindingBiodistributionBlood monocyteBody TissuesBreastBreast CancerBreast Cancer CellBreast Cancer ModelBreast Cancer PatientBreast Cancer TreatmentBreast Cancer cell lineBreast Conservation TreatmentBreast Tumor PatientBreast tumor cell lineBreast tumor modelBreast-Conserving SurgeryCancerousCancersCaspaseCaspase GeneCathepsinsCell BodyCell membraneCell-Death ProteaseCellsCharacteristicsCheckpoint inhibitorChemistryChemotherapy and RadiationChemotherapy and/or radiationClassificationClinicalCombined Modality TherapyComplexCouplingCysteine EndopeptidasesCysteine ProteaseCysteine ProteinasesCytoplasmic MembraneDeath RateDetectable Residual DiseaseDiseaseDisease remissionDisorderDistant CancerDistant MetastasisDoseDrug KineticsEffectivenessEpitheliumEsteroproteasesExcisionExhibitsExtirpationExtracellular Matrix ProteinsFemaleFormulationFutureGoalsHumanICE-like proteaseImageImage-Guided SurgeryImmuneImmune EvasionImmune MonitoringImmune checkpoint inhibitorImmune memoryImmune responseImmunesImmunityImmunocompetentImmunologic MemoryImmunologic MonitoringImmunologic StimulationImmunological MemoryImmunological MonitoringImmunological StimulationImmunomodulationImmunomonitoringImmunostimulationInbred BALB C MiceIndocyanine GreenInflammatoryIntratumoral heterogeneityLaser ElectromagneticLaser RadiationLasersLightLinkMacrophageMalignant Breast NeoplasmMalignant NeoplasmsMalignant TumorMammectomyMarrow monocyteMastectomyMeasuresMediatingMesenchymalMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsMicroscopicMinimal Residual DiseaseModern ManMolecular InteractionMultimodal TherapyMultimodal TreatmentMurineMusMyeloid-derived suppressor cellsMφNeoplasm MetastasisOperative ProceduresOperative Surgical ProceduresPathologyPatientsPeptidasesPeptide HydrolasesPharmacokineticsPhenotypePhotoradiationPlasma MembranePostoperativePostoperative PeriodPrimary NeoplasmPrimary TumorProtease GeneProteasesProteinasesProteinsProteolytic EnzymesRecurrenceRecurrentRecurrent Malignant NeoplasmRecurrent Malignant TumorRecurrent NeoplasmRecurrent tumorRemissionRemovalReportingResearchResearch SpecimenResidual CancersResidual NeoplasmResidual TumorsRiskRuptureSecondary NeoplasmSecondary TumorSolidSolid NeoplasmSolid TumorSpecimenSurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalSurgical marginsSystemSystematicsT-Cell ActivationTechnologyTherapeuticTimeTissuesTransfectionTumor CellTumor-associated macrophagesUjoveridinWofaverdinWomanWomen's mortalityactivate T cellsadaptive immune responseadjuvant treatmentanamnestic reactionangiogenesisanti-cancerbreast conservation surgerybreast conserving treatmentbreast tumor cellcancer biomarkerscancer markerscancer metastasiscancer microenvironmentcancer progressioncancer recurrencecancer surgerychemo/radiation therapychemotherapy and radiotherapycombination therapycombined modality treatmentcombined treatmentcystein proteasecystein proteinasecysteine endopeptidasecytokinedeath among femalesdeath among womendeath in femalesdeath in womendesigndesigningdetermine efficacyeffective therapyeffective treatmentefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationevaluate efficacyexamine efficacyfemale deathfemale mortalityfemale patientsfluorescence imagingfluorescent imagingheterogeneity in tumorshost responseimagingimmune check point inhibitorimmune competentimmune evasiveimmune modulationimmune regulationimmune system responseimmunogenicimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresponseimmunosuppressive myeloid cellsimprovedimproved outcomein situ vaccinein vivoindividuals with breast cancerinnovateinnovationinnovativeintra-operative imagingintra-tumoral heterogeneityintraoperative imagingintratumor heterogeneityirradiationmalignancymalignant breast tumormammary cancer modelmammary tumor modelminimally invasivemonocytemortality among femalesmortality among womenmortality in femalesmortality in womenmortality ratemouse modelmulti-modal therapymulti-modal treatmentmurine modelmyeloid suppressor cellsmyeloid-derived suppressive cellsnano particlenano-sized particlenanoparticlenanosized particleneoplasm progressionneoplasm recurrenceneoplasm/cancerneoplastic cellneoplastic progressionnoveloverexpressoverexpressionpathogenpatients being femalepatients being womenpatients who are femalepatients with breast cancerperson with breast cancerphotothermal therapyplasmalemmapreventpreventingradiation or chemotherapyrecruitresectionresidual diseaseresponseresponse to therapyresponse to treatmentsecondary immune responsesmall moleculestandard of caresuccesssuppressive myeloid cellssurgerysurgical imagingsynergismtargeted biomarkertargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttheranosticstherapeutic outcometherapeutic responsetherapy outcometherapy responsetreatment responsetreatment responsivenesstumortumor cell metastasistumor heterogeneitytumor microenvironmenttumor progressiontumorigenicuptakevirtualwomen patientswomen's death♀
Description preview
Abstract
Breast cancer (BCa) remains a leading cause of mortality among women globally, and current therapeutic
paradigms often fail to prevent tumor recurrence and metastasis. Despite surgical resection being a cornerstone
of treatment, residual tumor cells after surgery and the immune suppressive tumor microenvironment pose
significant barriers…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click